

The United States vs. Other Countries: Availability of New Medicines Varies

The proposed International Pricing Index Model would set U.S. prices for medicines covered under Medicare Part B based on the pricing policies of 14 foreign governments – many of which set prices artificially low, resulting in severe access restrictions for patients.

	New Medicines Available	Average Delay in Availability of New Medicines
 Greece	16%	31 months
 Ireland	41%	20 months
 Belgium	44%	22 months
 Czech Republic	44%	24 months
 Canada	46%	15 months
 France	50%	18 months
 Finland	51%	16 months
 Italy	51%	20 months
 Japan	51%	16 months
 Netherlands	53%	7 months
 Denmark	54%	12 months
 Austria	58%	11 months
 United Kingdom	59%	18 months
 Germany	63%	10 months
 United States	87%	0-3 months

Source: PhRMA analysis of IQVIA Analytics Link and FDA, EMA and PMDA data. June 2020. Note: New Active Substances (NASs) approved by the FDA, EMA and/or PMDA and first launched in any country between January 2011 and December 2019. Average delay represents the time in months since global first launch among NASs that have launched in a given country. IQVIA reports only the retail channel for Greece.